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IVIG-associated hemolysis2; therefore, only IgG was tested
by DAT. As the ABO system is a carbohydrate antigen
system,7 it was not surprising that the isoagglutinins eluted
from the DAT-positive patient samples were of the IgG2
subclass.4,6 This subclass is known to be associated with
carbohydrate antigens and studies previously reported have
shown that ABO isoagglutinins are primarily of the IgG2
subclass.4 IgG2 subclass antibodies also are known to interact
with the FcγRIIA receptor on mononuclear phagocytes,3,6,8,9
and this interaction can be enhanced by specific polymor-
phisms.8,9 Although the patients reported herein were not
tested for FcγRIIA polymorphisms, we previously showed in
a different cohort of patients with or without hemolysis that
there is no correlation of FcγR polymorphisms with IVIG-
associated hemolysis.3
Despite the caveat that only 10 of 22 patients’ DAT-
positive subclass could be determined, these results can still
provide some valuable conclusions, as we were able to test
8 patients who hemolyzed and 2 patients who did not
hemolyze. We conclude that in patients who develop a posi-
tive DAT following IVIG therapy the predominant antibody
opsonizing the patients’ autologous RBCs is an isoagglutinin
of IgG2 subclass. We further conclude that there is no corre-
lation of IgG2 or other subclasses to whether a patient will
hemolyze or not.
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ABO-associated antibody-mediated rejection
following A2B-to-B renal transplantation and
successful treatment with therapeutic plasma
exchange
Organ allocation policies allowing blood type A2(B) donor to
B recipient renal transplantation came into effect in December
2014 as an effort to increase allograft access for blood type B
transplant candidates. For B candidates to be listed to receive
A2(B) donor kidneys, a pretransplantation anti-A IgG titer using
A2 cells (A2-IgG) must be 4 or less (“low”). Long-term follow-
up has demonstrated that A2(B)-to-B transplants with previ-
ously low A2-IgG titers have noninferior clinical outcomes
when compared to B-to-B transplants.1,2
We report a case of a 64-year old B-positive male with
end-stage renal disease secondary to type 2 diabetes mellitus,
cirrhosis, and hypertension, who had been actively listed for
a renal transplant for 2 years. At the time of his transplant
from an A2B donor, his panel reactive antibodies demon-
strated 0% reactivity for both HLA class I and class II antigens,
and his A2-IgG was 1:1 or 1:2 by doubling dilution tubemethod
using the patient’s serum and A2 cells on four occasions; the
closest testing was 52 days before the transplant. Per institu-
tional protocol, his immunosuppression regimen consisted of
doi:10.1111/trf.15201
© 2019 AABB
LETTERS TO THE EDITOR
Volume 59, May 2019 TRANSFUSION 1883
thymoglobulin, tacrolimus, mycophenolate mofetil, and predni-
sone. His posttransplant course was complicated by slow serum
creatinine decrease in the context of supratherapeutic tacroli-
mus levels. He was discharged on Postoperative Day 4 with a
creatinine of 4.56 mg/dL.
The patient was readmitted on Postoperative Day 10 for
increased incisional drainage, leukocytosis, and rising creati-
nine. Imaging revealed a fluid collection around his allograft
that required surgical exploration and wound washout of
his fascial dehiscence. Culture of his abdominal fluid grew
Streptococcus viridans and coagulase-negative Staphylococcus.
At the time of wound washout on the next day of transplant,
an allograft biopsy was obtained that revealed diffuse peritub-
ular capillary C4d staining with occasional neutrophils sug-
gestive of acute antibody-mediated rejection; no evidence of
T-cell–mediated rejection was observed. Repeat HLA panel
reactive antibodies was negative, but his A2-IgG titer was ele-
vated to 128 (Fig. 1). Repeat testing 1 week later showed an
A2-IgG titer of 256; however, this was after administration of IVIG
(2 g/kg), which also contains ABO antibodies that have been var-
iably associated with hemolysis.3,4 Antimicrobial therapy for his
wound infection precluded additional immunosuppressive ther-
apy for rejection for another week. He then began a course of six
treatments of one plasma volume therapeutic plasma exchange
followed by IVIG administration (100 mg/kg) roughly every
other day per institutional protocol for renal antibody-mediated
rejection. During and following this course, his A2-IgG titers
declined steadily to 1:8 after 3 therapeutic plasma exchange pro-
cedures and his creatinine also gradually reduced (Fig. 1). Unfor-
tunately, the patient continued to have infectious events and
died at Postoperative Day 105 after developing disseminated
invasive aspergillosis.
Breimer et al.5 demonstrated weak A antigen expres-
sion on human renal endothelium and distal tubules in A2
individuals by immunohistochemistry. To our knowledge,
proven ABO-mediated antibody-mediated rejection has not
been reported in an A2(B) transplant to a B recipient. There
is strong circumstantial evidence supporting stimulation of
A2-IgG titer by the transplanted graft, especially in this
patient with serial negative A2-IgG titers before transplant.
We also think the rise in isohemagglutinin was likely
enhanced by infection. We highlight this case to demon-
strate the possibility of developing A2-IgG following trans-
plant of an A2 kidney to a non-A recipient, as well as to
offer an anecdote of effective treatment with therapeutic
plasma exchange followed by IVIG that subsequently
decreased antibody titers and creatinine.
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Fig. 1. Anti-A2 IgG titer and serum creatinine over patient post-operative clinical course.
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